Here is the design of a clinical trial:

Official Title: Adjunctive Granisetron Therapy in Patients With Sepsis or Septic Shock：A Single-center, Randomized, Controlled, Single-blind Clinical Trial

Included conditions:
- Sepsis

Study Armgroups:
- {'label': 'granisetron group', 'type': 'EXPERIMENTAL', 'description': '3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.', 'interventionNames': ['Drug: Granisetron Hydrochloride']}
- {'label': 'placebo group', 'type': 'PLACEBO_COMPARATOR', 'description': 'Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.', 'interventionNames': ['Drug: Placebo（Normal saline）']}

Interventions:
- {'type': 'DRUG', 'name': 'Granisetron Hydrochloride', 'description': 'Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.', 'armGroupLabels': ['granisetron group'], 'otherNames': ['Selective 5-hydroxytryptamine 3 receptor inhibitor']}
- {'type': 'DRUG', 'name': 'Placebo（Normal saline）', 'description': 'therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.', 'armGroupLabels': ['placebo group'], 'otherNames': ['0.9% saline']}

Primary Outcomes:
- {'measure': 'all-cause mortality rate', 'description': 'All-cause mortality rate from the enrollment to the 28th days', 'timeFrame': '28 days'}

Please estimate the sample size based on the assumption: 
The significance level is set at 0.05, power at 80% (β = 0.2), and an additional 15% is added to account for shedding and loss of follow-up.
2.11
        Sample size
        According to previous clinical experience, the mortality rate of sepsis in this study center is about 33%. Our sample size was calculated to detect a 20% difference in mortality on day 28 between the 2 groups with a 2-tailed test, a = 0.05, Î²â=â0.2 (power = 80%). Considering some factors such as shedding and loss of follow-up, an additional 15% of the sample size was added, resulting in a total of 154 patients, 77 in the control group, and 77 in the treatment group.